{"filing": {"accession": "0001104659-26-050429", "cik": "0001377121", "ticker": "PTGX", "company_name": "Protagonist Therapeutics, Inc", "form_type": "DEF 14A", "filing_type": "DEF 14A", "filing_date": "2026-04-28", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1377121/000110465926050429/0001104659-26-050429-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1377121/000110465926050429/0001104659-26-050429-index.htm", "period_of_report": "2026-06-17"}, "html_url": "/api/filings/000110465926050429/stream", "exhibits": [], "sections": [], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": "\u200b/s/ Dinesh V. Patel, Ph.D.\u200bDinesh V. Patel, Ph.D.President and Chief Executive Officer\u200b\u200b\u200b\u200b"}, {"table_index": 1, "table_type": "text", "caption": null, "header_text": "\u200bQUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING\u200b\u200b\u200b\u200b1\u200b\u200b"}, {"table_index": 2, "table_type": "text", "caption": null, "header_text": "\u200bProposalNo.\u200b\u200bDescription\u200b\u200bVote Required forApproval\u200b\u200bEffect of Abstentions\u200b\u200bEffect of BrokerNon-Votes, If Any\u200b"}, {"table_index": 3, "table_type": "text", "caption": null, "header_text": "\u200bProposalNo.\u200b\u200bDescription\u200b\u200bVote Required forApproval\u200b\u200bEffect of Abstentions\u200b\u200bEffect of BrokerNon-Votes, If Any\u200b"}, {"table_index": 4, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200bAudit\u200b\u200bCompensation\u200b\u200bNominating andCorporateGovernance\u200b\u200bResearch\u200b"}, {"table_index": 5, "table_type": "text", "caption": null, "header_text": "\u200b\u200b\u200bFiscal Year EndedDecember 31,\u200b"}, {"table_index": 6, "table_type": "text", "caption": null, "header_text": "\u200b\u200b\u200b2025\u200b\u200b2024\u200b\u200b2023\u200b"}, {"table_index": 7, "table_type": "text", "caption": null, "header_text": "\u200b\u200b\u200bDecember 31, 2025\u200b"}, {"table_index": 8, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200bAge\u200b\u200bPosition\u200b"}, {"table_index": 9, "table_type": "text", "caption": null, "header_text": "\u200b\u200b\u200bBeneficial Ownership(1)\u200b"}, {"table_index": 10, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200bPosition\u200b"}, {"table_index": 11, "table_type": "text", "caption": null, "header_text": "\u200bCEO Target Compensation*\u200b\u200bOther NEO Average Target Compensation*\u200b"}, {"table_index": 12, "table_type": "text", "caption": null, "header_text": "\u200b\u200b\u200bPay for Performance.The Compensation Committee believes in aligning pay with performance. As such, the significant majority of our executive compensation is variable and at-risk, with a substantial"}, {"table_index": 13, "table_type": "text", "caption": null, "header_text": "\u200bAgios Pharmaceuticals, Inc.\u200b\u200bIDEAYA Biosciences, Inc.\u200b"}, {"table_index": 14, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200b2025 BaseSalary\u200b\u200b2024 BaseSalary\u200b\u200bYear-Over-YearPercentage Change\u200b"}, {"table_index": 15, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200b2025 Target Bonus(% of Base Salary)\u200b"}, {"table_index": 16, "table_type": "text", "caption": null, "header_text": "Performance Goal and Weighting\u200b\u200bAdditional Detail on Goal\u200b\u200bPerformance Assessment\u200b"}, {"table_index": 17, "table_type": "text", "caption": null, "header_text": "Performance Goal and Weighting\u200b\u200bAdditional Detail on Goal\u200b\u200bPerformance Assessment\u200b"}, {"table_index": 18, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200b2025 BonusEarned\u200b\u200bBonus Achieved(as % ofTarget Bonus)\u200b"}, {"table_index": 19, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200bStock Options($)\u200b\u200bStockOptions (#)\u200b\u200bRestricted StockUnits ($)\u200b\u200bRestrictedStock Units (#)\u200b"}, {"table_index": 20, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200bGrant Date\u200b\u200bNumber ofSecuritiesUnderlyingAward\u200b\u200bExercisePrice(1)\u200b\u200bGrant DateFair Value\u200b\u200bPercentage Change in the Closing MarketPrice of the Securities Underlying the AwardBetween the Trading Day"}, {"table_index": 21, "table_type": "text", "caption": null, "header_text": "Name and PrincipalPosition\u200b\u200bYear\u200b\u200bSalary ($)\u200b\u200bBonus($)\u200b\u200bStockAwards ($)(1)\u200b\u200bOptionAwards($)(1)\u200b\u200bNon-EquityIncentivePlanCompensation($)\u200b\u200bAll OtherCompensation($)(2)\u200b\u200bTotal ($)\u200b"}, {"table_index": 22, "table_type": "text", "caption": null, "header_text": "\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200bEstimated FuturePayments Under Non-EquityIncentive Plan Awards\u200b\u200bAll OtherStockAwards:Number ofShares ofStock orUnits (#)\u200b\u200bAll OtherOptionAwards:Numberof SecuritiesUnderlyingOptions (#)\u200b\u200bExerc"}, {"table_index": 23, "table_type": "text", "caption": null, "header_text": "\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200bOption Awards\u200b\u200bStock Awards\u200b"}, {"table_index": 24, "table_type": "text", "caption": null, "header_text": "\u200b\u200b\u200bOption Awards\u200b\u200bStock Awards\u200b"}, {"table_index": 25, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200b\u200b\u200b\u200bVoluntaryTermination ($)\u200b\u200bInvoluntaryTermination(WithoutCause orfor GoodReason) not inConnectionwith a Change inControl ($)\u200b\u200bInvoluntaryTermination inConnectionwith a Change inControl ($)\u200b\u200bCh"}, {"table_index": 26, "table_type": "financial", "caption": null, "header_text": "\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200bAverageSummaryCompensationTable Total forNon-PEONEOs(3)\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200bValue of Initial Fixed$100 InvestmentBased On:\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b\u200b"}, {"table_index": 27, "table_type": "text", "caption": null, "header_text": "Compensation Actually Paid to PEO\u200b\u200b2025\u200b"}, {"table_index": 28, "table_type": "text", "caption": null, "header_text": "Average Compensation Actually Paid to Non-PEO NEOs\u200b\u200b2025\u200b"}, {"table_index": 29, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200bFee Earned orPaid in Cash($)(1)\u200b\u200bStockAwards($)(2)(3)\u200b\u200bOptionAwards($)(2)(3)\u200b\u200bAll OtherCompensation($)\u200b\u200bTotal($)\u200b"}, {"table_index": 30, "table_type": "text", "caption": null, "header_text": "Name\u200b\u200bAggregate Number of RSUsOutstanding as ofDecember 31, 2025\u200b\u200bAggregate Number of OptionAwards Outstanding as ofDecember 31, 2025\u200b"}, {"table_index": 31, "table_type": "text", "caption": null, "header_text": "Plan Category(1)\u200b\u200bNumber ofSecurities to BeIssued UponExercise ofOutstandingOptions,Warrants andRights (a)\u200b\u200bWeightedAverageExercise Priceof OutstandingOptions,Warrants andRights(2)(b)\u200b\u200bNumber ofSecuri"}], "exhibits_pending": true, "cdn_html": true, "response_time_ms": 27}